ASCP Corner: Real-Life Switching Strategies With Second-Generation Antipsychotics
Christoph U. Correll, MD
J Clin Psychiatry 2006;67(1):160-161
© Copyright 2019 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
In last month’s ASCP Corner,1 the issue of real-life dosing of second-generation antipsychotics (APs) in patients showing an inadequate response to recommended doses was discussed. The article focused on reasons why the dose ranges derived from premarketing registration trials may not be generalizable to certain clinical populations that are systematically excluded from these important efficacy studies.
This month’s column will examine different switch strategies of second-generation APs in patients showing an inadequate response to an appropriate trial with an AP, again addressing the question of generalizability of the results from randomized controlled trials comparing different switch strategies.